

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2022 May 15; 14(5): 947-1066



### REVIEW

- 947** Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics  
*Said I, Ahad H, Said A*
- 959** *Helicobacter pylori*, gastric microbiota and gastric cancer relationship: Unrolling the tangle  
*Liatsos C, Papaefthymiou A, Kyriakos N, Galanopoulos M, Doulberis M, Giakoumis M, Petridou E, Mavrogiannis C, Rokkas T, Kountouras J*
- 973** *EFNA1* in gastrointestinal cancer: Expression, regulation and clinical significance  
*Chu LY, Huang BL, Huang XC, Peng YH, Xie JJ, Xu YW*

### MINIREVIEWS

- 989** Scoping out the future: The application of artificial intelligence to gastrointestinal endoscopy  
*Minchenberg SB, Walradt T, Glissen Brown JR*

### ORIGINAL ARTICLE

#### Retrospective Study

- 1002** Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer  
*Li YT, Zhou XS, Han XM, Tian J, Qin Y, Zhang T, Liu JL*
- 1014** Preoperative prediction of malignant potential of 2-5 cm gastric gastrointestinal stromal tumors by computerized tomography-based radiomics  
*Sun XF, Zhu HT, Ji WY, Zhang XY, Li XT, Tang L, Sun YS*
- 1027** Improving the accuracy and consistency of clinical target volume delineation for rectal cancer by an education program  
*Zhang YZ, Zhu XG, Song MX, Yao KN, Li S, Geng JH, Wang HZ, Li YH, Cai Y, Wang WH*

#### Observational Study

- 1037** Digital single-operator cholangioscopy for biliary stricture after cadaveric liver transplantation  
*Yu JF, Zhang DL, Wang YB, Hao JY*

### CASE REPORT

- 1050** Primary hepatic angiosarcoma manifesting as hepatic sinusoidal obstruction syndrome: A case report  
*Ha FS, Liu H, Han T, Song DZ*

- 1057** Successful treatment of pancreatic accessory splenic hamartoma by laparoscopic spleen-preserving distal pancreatectomy: A case report

*Xu SY, Zhou B, Wei SM, Zhao YN, Yan S*

### **CORRECTION**

- 1065** Correction to “Efficacy and safety of endoscopic resection in treatment of small gastric stromal tumors: A state-of-the-art review”

*Chen ZM, Peng MS, Wang LS, Xu ZL*

## ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Zilvinas Dambrauskas, MD, PhD, Professor, Department of Surgery and Institute for Digestive System Research, Lithuanian University of Health Sciences, Kaunas 50161, Lithuania. zilvinas.dambrauskas@lsmuni.lt

## AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

## INDEXING/ABSTRACTING

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

## RESPONSIBLE EDITORS FOR THIS ISSUE

**Production Editor:** Ying-Yi Yuan; **Production Department Director:** Xiang Li; **Editorial Office Director:** Ya-Juan Ma.

### NAME OF JOURNAL

*World Journal of Gastrointestinal Oncology*

### ISSN

ISSN 1948-5204 (online)

### LAUNCH DATE

February 15, 2009

### FREQUENCY

Monthly

### EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

### EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

### PUBLICATION DATE

May 15, 2022

### COPYRIGHT

© 2022 Baishideng Publishing Group Inc

### INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

### GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

### GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

### PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

### PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

### ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

### STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

### ONLINE SUBMISSION

<https://www.f6publishing.com>



## *Helicobacter pylori*, gastric microbiota and gastric cancer relationship: Unrolling the tangle

Christos Liatsos, Apostolis Papaefthymiou, Nikolaos Kyriakos, Michail Galanopoulos, Michael Doulberis, Marios Giakoumis, Evangelia Petridou, Christos Mavrogiannis, Theodore Rokkas, Jannis Kountouras

**Specialty type:** Gastroenterology and Hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Dong QJ, China

**Received:** March 19, 2021

**Peer-review started:** March 19, 2021

**First decision:** May 3, 2021

**Revised:** May 12, 2021

**Accepted:** April 9, 2022

**Article in press:** April 9, 2022

**Published online:** May 15, 2022



**Christos Liatsos, Apostolis Papaefthymiou, Nikolaos Kyriakos, Michail Galanopoulos, Marios Giakoumis,** Department of Gastroenterology, 401 General Military Hospital of Athens, Athens 11525, Greece

**Apostolis Papaefthymiou,** Gastroenterology, University Hospital of Larissa, Larissa 41336, Greece

**Michael Doulberis,** Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau 1234, Switzerland

**Evangelia Petridou,** Department of Microbiology, "Agia Sofia" Paediatric Hospital, Goudi, Athens 11527, Greece

**Christos Mavrogiannis,** Gastrointestinal and Liver Unit, Faculty of Nursing, Kifissia General and Oncology Hospital, Kaliftaki, N.Kifisia 14564, Greece

**Theodore Rokkas,** Gastroenterological Clinic, Henry Dunant Hospital, Athens 11525, Greece

**Jannis Kountouras,** Department of Internal Medicine, Second Medical Clinic, Ippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki 41336, Macedonia, Greece

**Corresponding author:** Christos Liatsos, FEBG, MD, PhD, Director, Department of Gastroenterology, 401 General Military Hospital of Athens, Panagioti Kanellopoulou Ave, Athens 11525, Greece. [cliatsos@yahoo.com](mailto:cliatsos@yahoo.com)

### Abstract

*Helicobacter pylori* infection (*Hp-I*) represents a typical microbial agent intervening in the complex mechanisms of gastric homeostasis by disturbing the balance between the host gastric microbiota and mucosa-related factors, leading to inflammatory changes, dysbiosis and eventually gastric cancer. The normal gastric microbiota shows diversity, with *Proteobacteria* [*Helicobacter pylori* (*H. pylori*) belongs to this family], *Firmicutes*, *Actinobacteria*, *Bacteroides* and *Fusobacteria* being the most abundant phyla. Most studies indicate that *H. pylori* has inhibitory effects on the colonization of other bacteria, harboring a lower diversity of them in the stomach. When comparing the healthy with the diseased stomach, there is a change in the composition of the gastric microbiome with increasing abundance of *H. pylori* (where present) in the gastritis stage, while as the gastric carcinogenesis cascade progresses to gastric cancer, the oral and intestinal-type

pathogenic microbial strains predominate. *Hp*-I creates a premalignant environment of atrophy and intestinal metaplasia and the subsequent alteration in gastric microbiota seems to play a crucial role in gastric tumorigenesis itself. Successful *H. pylori* eradication is suggested to restore gastric microbiota, at least in primary stages. It is more than clear that *Hp*-I, gastric microbiota and gastric cancer constitute a challenging tangle and the strong interaction between them makes it difficult to unroll. Future studies are considered of crucial importance to test the complex interaction on the modulation of the gastric microbiota by *H. pylori* as well as on the relationships between the gastric microbiota and gastric carcinogenesis.

**Key Words:** *Helicobacter pylori* infection; Gastric microbiota; Gastric cancer; Oncogenesis; Dysbiosis; *Helicobacter pylori* eradication

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Gastric adenocarcinoma is a leading cause of cancer-related death in the world. Chronic gastric infection caused by *Helicobacter pylori* (*H. pylori*) is the strongest identified risk factor for gastric adenocarcinoma, prompting the World Health Organization to classify it as a class I carcinogen. It has been shown that in *H. pylori*-colonized patients, this pathogen accounts for more than 90% of all gastric microbiota modifying healthy microbiota and reducing its overall diversity. In this review, we tackle the complicated relationship between *H. pylori*, gastric microbiota and gastric cancer in an effort to unroll this tangle.

**Citation:** Liatsos C, Papaefthymiou A, Kyriakos N, Galanopoulos M, Doulberis M, Giakoumis M, Petridou E, Mavrogiannis C, Rokkas T, Kountouras J. *Helicobacter pylori*, gastric microbiota and gastric cancer relationship: Unrolling the tangle. *World J Gastrointest Oncol* 2022; 14(5): 959-972

**URL:** <https://www.wjgnet.com/1948-5204/full/v14/i5/959.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v14.i5.959>

## INTRODUCTION


Gastric cancer (GC) has been recognized as a global health concern; it is still the fifth most frequent global malignancy and one of the main causes of cancer-related death[1]. Likewise, *Helicobacter pylori* infection (*Hp*-I), an important public health burden affecting more than half of the global population[2], is related with the majority of GC, with an estimate between 74.7% to more than 90% of the new non-cardia GC cases[1,3].

Regarding the interaction between *Hp*-I and GC, relevant mechanisms known for many years have been studied and are constantly being enriched with new data (Figure 1)[4-17]. In this regard, arising evidence indicates that *Helicobacter pylori* (*H. pylori*), as the most important member of abnormal gastric microbiota (GM), might induce gastric microbiome modifications[11] thereby possibly leading to gastric oncogenesis. The gastric flora may be involved in the *H. pylori*-related oncogenicity, and the variations in the GM composition of patients with GC, intestinal metaplasia (IM) and chronic gastritis are defined [18]. For instance, *Campylobacter* is among the most influential genera in *H. pylori*-associated atrophic gastritis and gastric atrophy-induced alterations of the GM, namely gastric dysbiosis, might contribute to gastric tumorigenic effect[1]. Moreover, *H. pylori*-related metabolic syndrome induces dysbiosis of gastrointestinal tract (GIT) microbiota, thereby contributing to lower and upper GIT carcinogenesis including GC[19-21]. However, the interaction between the host, microbiota and *H. pylori* in the pathogenesis of GC still has to be fully elucidated[22].

Based on recent data, this review attempts to unroll the tangle regarding the interaction between *Hp*-I, GM and GC.

## GASTRIC MICROBIOTA COMPOSITION

The GIT (mainly intestine) is colonized by  $1-4 \times 10^{15}$  microorganisms, co-existing in a balanced relationship[22]; the GIT microbiota is estimated to be up to 2 kg and affects health and disease[23]. The majority of the bacteria found in the adults' gut consists of *Bacteroides* and *Parabacteroides*[23]. The anaerobic environment of intestinal lumen does not facilitate aerobic pathogens colonization and development under normal conditions, though anaerobic and facultative pathogenic species can invade it and promote diseases. Each site of the GIT has a unique distribution of microflora; when compared



**Figure 1** Possible mechanisms involved (A) in the etiology of non-cardiac gastric cancer (intestinal type) resulting in the classical cascade of Correa histopathological precancerous lesions (B) as seen in an upper gastrointestinal endoscopy. *Hp*-1: *Helicobacter pylori* infection; GC: Gastric cancer; PPIs: Proton pump inhibitors; CagA: Cytotoxin-associated gene A; VacA: Vacuolating cytotoxin A; GGT:  $\gamma$ -glutamyl transpeptidase; BabA: Blood-group-antigen-binding adhesin; SabA: Sialic acid-binding adhesin; OipA: Outer inflammatory protein; NapA: Neutrophil activation protein A; EMT: Epithelial-mesenchymal transition; ROS/RNS: Reactive oxygen species/Reactive nitrogen species; EGFR: Epidermal growth factor receptor; SPEM: Spasmolytic polypeptide-expressing metaplasia; CSC: Cancer stem cell; BMDSCs: Bone marrow-derived stem cells; IEN: Intraepithelial neoplasia.

with the stomach and duodenum, bacteria density increases in the jejunum/ileum and colon. To yield the optimal conditions for their common interaction and survival, host and microbes have developed specific mechanisms; the disruption of those mechanisms triggers an imbalance in microbial species abundance, termed dysbiosis, which is incriminated for gut barrier dysfunction and induction of inflammatory response. In this regard, the failure to regulate the composition (microbial diversity), probably occurs during the beginning and course of several diseases including malignancies, such as GC[24].

Until recently, the gastric environment was considered as sterile, probably due to increased acidity, and the microbiota was believed to be isolated in the small intestine and colon. Subsequently, identifying *H. pylori* focused the attention on the gastric microbiota as “an ecological niche for bacteria” [23]. Emerging data have revealed that there is a broad range of microorganisms in the stomach with a density of  $10^1$  to  $10^3$  colony forming units/g[25,26]. Gastric microbiome is composed of bacteria ingested mainly through the oro-respiratory tract and secondary from the intestine by transpyloric biliary reflux [27,28]. Most of those microorganisms cannot resist indigenous gastric defensive mechanisms and there are data indicating which microorganisms permanently colonize the gastric mucosa, other than *H. pylori*. Relative reports suggested that the predominant phyla in the gastric mucosa consist of *Streptococcus*, *Rothia*, *Lactobacillus*, *Veillonella*, *Prevotella*, *Neisseria* and *Hemophilus*, counting more than one hundred sorts[28,18]. Specifically, *H. pylori*, represents the most important member of the GM family with the highest relative abundance. Additional GM includes *Proteobacteria*, *Firmicutes*, *Actinobacteria*, *Bacteroidetes* and *Fusobacteria* being the 5 most abundant phyla[18], in children and adults[29]. In culture-based studies where cultures of gastric juice or mucosa biopsies were examined, numerous members of the *Firmicutes*, *Proteobacteria*, *Actinobacteria* and *Fusobacteria* phyla were identified, while yeasts were recognized in a relatively low abundance[30,31]. Laboratory molecular techniques with high sensitivity indicated that *Streptococcus*, *Prevotella*, *Neisseria*, *Veillonella* and *Rothia* represent the main bacterial populations in the gastric tissue, with *Streptococcus* being the most dominant genus[32-36]. Sung *et al* [37] revealed heterogeneity in the flora of gastric fluid and mucosa. Gastric mucosa has a greater flora richness while gastric juice has a greater flora diversity[37]. The presence of bacteria in gastric juice could be just transient as a result of their ingestion with food, drinks or saliva without colonizing the gastric mucosa so they create a fictional image of the real diversity[18].

More specifically, Bik *et al*[36] by introducing a small subunit 16S rDNA clone library approach, described a diverse population of 128 phylotypes (totally 1833 bacterial isolates obtained from gastric



biopsies of 23 healthy adults) within gastric mucosal samples with the majority of bacteria belonging to the five abovementioned major groups- *Proteobacteria*, *Firmicutes*, *Actinobacteria*, *Bacteroidetes* and *Fusobacteria* phyla[36]. A lot of similar studies confirmed the presence and proportion of these phyla[4, 38-41]. Table 1 shows the taxonomy of most prevalent GM at phylum and genus level.

## IMPACT OF *HP-I* ON GASTRIC MICROBIOTA COMPOSITION

Regarding *Hp-I*, its impact on the GM remains to be clarified. While Bik *et al*[36] did not depict an impact of the occurrence of *H. pylori* in gastric biopsies on the composition of GM, several subsequent studies characterize *H. pylori* as the regulator of the GM community. Andersson *et al*[42] revealed that *H. pylori* was the dominant bacterium whenever isolated, though its absence was associated with a diverse microbiota. Analytically, in samples from *H. pylori*(+) individuals, *H. pylori* was the mainstay species (ninety percent) of the samples examined by 454 pyro-sequencing. Thirty-three phylotypes were recognized solely, 229 less when compared with *H. pylori*(-) individuals[42]. The abovementioned signifies that *H. pylori* has inhibitory effects on the colonization of other bacteria harboring a significantly lower diversity of them in the stomach. The GM in *H. pylori* negative patients was mainly dominated by the same phyla, though with diverse percent abundances: 52.6% *Proteobacteria*, 26.4% *Firmicutes*, 12% *Bacteroidetes* and 6.4% *Actinobacteria*[43]. The common genera observed in *H. pylori* negative individuals included *Gemella*, *Prevotella* and *Streptococcus*[42].

In another study which introduced DNA microarrays to characterize the GM in 12 corpus biopsy samples (eight *H. pylori* positive), Maldonado-Contreras *et al*[44] isolated 44 phyla with four dominant *Proteobacteria*, *Firmicutes*, *Actinobacteria*, and *Bacteroidetes*. *Hp-I* augmented the relative abundance of non-*H. pylori* – *Proteobacteria*, *Spirochaetes*, and *Acidobacteria* whereas lessening the relative abundance of *Actinobacteria*, *Bacteroidetes* and *Firmicutes*, compared to uninfected stomachs[44]. An additional study from Mongolia showed that patients infected with *H. pylori* exhibited a significantly lesser bacterial richness and Shannon and Simpson indices[45,46] compared with *H. pylori* negative arms. Moreover, enrichment of *Firmicutes*, *Fusobacteria*, *Bacteroidetes* and *Actinobacteria* at phylum level was shown in patients with *H. pylori* negative gastritis by the linear discriminant analysis effect size analysis[47].

Miao *et al*[48] studied the effect of *H. pylori* eradication in microbiota composition and found that GM profiles between *H. pylori* negative groups and previously *H. pylori* positive groups four months after successful eradication therapy were almost the same[48].

Table 2 shows the relative abundance of GM at phylum level among *H. pylori* positive and *H. pylori* negative patient groups. In particular, we present the minimum and the maximum values across the studies[36,42,43,47,48]. Also, we calculated the pooled percentages and the relative 95% confidence intervals. Among *H. pylori* positive patient groups, proteobacteria were more frequent, while among *H. pylori* negative patient groups, firmicutes and proteobacteria were more frequent.

## IMPACT OF FACTORS ON GASTRIC MICROBIOTA COMPOSITION BEYOND *HP-I*

Beyond *H. pylori*, the composition of GM could be modified by some other factors such as dietary habits, age, ethnicity, medication use and severity of gastric mucosa inflammation[18,27,49-53].

Proton pump inhibitor (PPI) raises the pH in the stomach thereby altering the GM. Likewise, PPIs-driven gastric hypo-chlorhydria can cause substantial changes in gut microbiota composition[54,55]. Two possible mechanisms by which the mentioned PPIs can influence the GM composition have been proposed: (1) By targeting directly bacterial and fungal proton pumps; and (2) By disturbing the natural gastric microenvironment through the gastric pH alkalization[56]. More specifically, GM of patients on PPIs therapy has more abundant bacteria compared to patients on H2RAs and untreated control. The composition of microbiota was quite similar to that of oropharyngeal or fecal bacteria[26]. Paroni Sterbini *et al*[57] showed a significant increase in the relative abundance of *Streptococcus* in patients taking PPIs irrespective of *H. pylori* status; they revealed that *Streptococcus* can be an independent indicator of the gastric microbiome changes in dyspeptic patients secondary to the use of PPIs[57]. On the other hand, Parsons *et al*[40] by using 16S rRNA sequencing in gastric samples, showed that patients receiving PPIs had relatively few changes in the GM compared to healthy controls[39]. Besides, numerous reports indicated that the *H. pylori* moving from the antrum to body and fundus of the stomach is recorded particularly by long-term PPIs usage[58]. Thus, *Hp-I* eradication is proposed for patients who received long-term PPI usage in order to prevent the proinflammatory trigger and thereby decreasing GC potential. Antibiotic ingestion also effects gastrointestinal microflora. Mason *et al*[59] revealed that treatment with cefoperazone caused changes in GM with an overgrowth of *Enterococci* and a decrease of *Lactobacilli*[59].

Attempting to correlate gastric mucosal inflammation with GM, a rise in *Streptococcus* and a reduction in *Prevotella* was found in patients with atrophic gastritis *vs* healthy subjects[36]. Patients with autoimmune atrophic gastritis exhibited a larger concentration of *Firmicutes* than patients with chronic atrophic gastritis (CAG) and a greater variety of microbial species than *H. pylori*-induced atrophic



**Table 1 Taxonomy of the most prevalent gastric microbiota at phylum and genus level**

Phylum	Genus
Proteobacteria	<i>Helicobacter</i> , <i>Enterobacteriaceae</i> unknown, <i>Acinetobacter</i> , <i>Pseudomonas</i> , <i>Haemophilus</i> , <i>Agrobacterium</i> , <i>Halomonas</i> , <i>Shewanella</i> , <i>Sphingomonas</i> , <i>Methylobacterium</i> , <i>Aquabacterium</i>
Bacteroidetes	<i>Prevotella</i> , <i>Chryseobacterium</i>
Firmicutes	<i>Streptococcus</i> , <i>Clostridium</i> , <i>Lactobacillus</i> , <i>Staphylococcus</i> , <i>Faecalibacterium</i> , <i>Veillonella</i> , <i>Bacillus</i> , <i>Peptostreptococcus</i> , <i>Selenomonas</i> , <i>Phascolarctobacterium</i> , <i>Gemella</i> , <i>Roseburia</i> , <i>Megamonas</i> , <i>Gemmiger</i> , <i>Lactococcus</i> , <i>Granulicatera</i> , <i>Dialister</i> , <i>Alcaliphylus</i> , <i>Ruminococcus</i> , <i>Blautia</i>
Fusobacteria	<i>Fusobacterium</i> , <i>Leptotrichia</i>
Actinobacteria	<i>Propionibacterium</i> , <i>Corynebacterium</i> , <i>Arthrobacter</i>
Spirochaetes	<i>Bacteroides</i>
Acidobacteria	<i>Streptophyta</i> , <i>Sphingobacterium</i> , <i>Pedobacter</i>

**Table 2 Relative abundance of gastric microbiota at phylum level among *Helicobacter pylori* positive and *Helicobacter pylori* negative patient groups**

Phylum	<i>H. pylori</i> -positive			<i>H. pylori</i> -negative		
	Minimum	Maximum	Pooled (95%CI)	Minimum	Maximum	Pooled (95%CI)
Proteobacteria	68.7	96.7	88.4 (75.4-95.9)	10.8	52.6	27.9 (12.7-43.9)
Bacteroidetes	0.8	8.3	3.1 (1.1-6.0)	11.1	30.0	20.8 (12.7-28)
Firmicutes	1.3	14.7	6.2 (1.8-12.9)	16.3	29.9	31.1 (20.5-40.1)
Fusobacteria	0.1	1.6	1.1 (0.2-2.3)	1.1	6.1	3.5 (1.6-6.1)
Actinobacteria	0.2	3.1	1.2 (0.4-2.5)	2.8	46.8	16.7 (2.4-37.2)

Values are expressed as percentages. CI: Confidence interval; *H. pylori*: *Helicobacter pylori*.

gastritis. This might be due to the differences in gastric acidity between the two conditions or additional factors such as their different immune profiles[39]. Researchers from Mexico obtained gastric tissue from patients with non-atrophic gastritis (NAG), IM and intestinal type GC through extraction of DNA for microbiota analyses using microarray methods and showed that bacterial diversity steadily decreased from NAG to IM to GC[59].

## THE INTERACTION BETWEEN GASTRIC MICROBIOTA AND GASTRIC CANCER

The existence of multiple homeostasis mechanisms that take place in the human stomach is a well-recognized phenomenon contributing to health maintenance by balancing the interaction between host gastric microbial diversity and mucosa-related factors[60,61]. When this balance is interrupted, a cascade of events occurs resulting in the emergence of inflammatory changes, dysbiosis and consequently, diseases including GC[36].

The mentioned hypochlorhydria appears to promote a decrease in microbial heterogeneity as well as the development of microorganisms which exhibit genotoxic changes, and raising the ratio of nitrate to nitrite reductase microbe capacities implicated in gastric oncogenesis. Furthermore, the bacterial balance differentiates by raising the stomach pH, giving growth mostly of oral bacteria, such as *Streptococcus anginosus*, *Peptostreptococcus stomatis*, *Slackia exigua* and *Parvimonas micra* as well as *Dialister pneumosintes*. Such bacteria might play a role in GC progression via the induction of various metabolic pathways[62]. Thus, to improve the understanding of the influence of promoting the survival and spread of potentially genotoxic bacteria in the stomach and other GIT locations, it will be critical to describe the properties of the mentioned PPIs in GM composition. Nevertheless, no consensus exists regarding the role of PPIs in GC development. Based on a number of meta-analyses and studies, there is an increased GC risk in patients using PPIs for a long time period[63] (approximately 2.4 times more than non-users), despite *H. pylori* eradication[4,64,65].

*Hp*-I is a precise paradigm of the GM homeostasis disturbance sequelae[66]. The *H. pylori*-related inflammatory effects primarily act on the mucosal surface of the stomach variably affecting the production of mucin[67]. Differentiations of the latter seem to play a crucial role regarding the gastric carcinogenesis pathway[9]. Nevertheless, it should be stated that studies on the *H. pylori*-related mucin

production changes have not yet been able to sort out whether this GC sequelae results in dysbiosis in the stomach or, conversely, to microbial diversity. These effects could be the backbone of GC development, given the fact that at the last stage of gastric malignancy oral or intestinal-type bacteria are predominantly discovered, something not seen in premalignant conditions (chronic gastritis, atrophy and IM) where *H. pylori* abundance is more than clear. Whether this phenomenon is due to tumor-related mucin type differentiation, possibly resulting in GC-related microbiota must be elucidated[68].

As already stated, earlier studies have shown that *H. pylori* negative individuals exhibit a significant variability in microbiota composition which mainly consists of *Proteobacteria*, *Firmicutes*, *Actinobacteria*, *Bacteroidetes* and *Fusobacteria*. On the contrary, the stomach of *H. pylori* positive patients is almost exclusively colonized by this infectious pathogen[42]. In line with this observation, it should be highlighted that from a specific point and beyond, the GC progress seems not to be related with *H. pylori* presence, since the gastric adenocarcinoma microbiota mainly consists of intestinal and oral bacterial genera, and in addition this progression can happen even after successful *H. pylori* treatment (Figure 2)[67]. Similar findings emerged from the study by Yu *et al*[27] who investigated 160 individuals with gastric malignancy residing in China and Mexico. They showed that in the non-cancerous gastric regions, the *H. pylori* presence was significantly high in contrast to the GC site with depletion even in the absence of *H. pylori*. The difference in microbiota diversity that patients with advanced malignant lesions exhibited was further verified in many studies which revealed a marked presence of *Lactobacillus*, *Streptococcaceae*, *Staphylococcus*, *Clostridium* and *Fusobacterium* among others, underlying the crucial role those intestinal microbes play[63,69]. Lastly, Robinson *et al*[70] showed, after utilizing an advanced computer-based search algorithm, that GC was the second most diversely abundant neoplasm in terms of bacterial DNA molecules with dominant species highly comprising *Pseudomonas* and not *H. pylori*.


The above studies and their subsequent findings have been verified to an accountable level by well-designed animal model experiments, especially in C57BL/6 mice, where their stomach microbiota consisted of similar bacteria categories to those found in humans, namely *Firmicutes*, *Bacteroidetes*, *Proteobacteria* and *Actinobacteria*[71]. For instance, according to Lofgren *et al*[72], the *H. pylori*-related gastritis not only resulted in decreased GM variety (as seen in human individuals), but also significantly extended the interval to gastric malignancy emergence, especially when the only pathogen was *H. pylori*. The above interesting outcome was confirmed by the study of Lertpiriyapong *et al*[73], who showed that by adding even a small number of intestinal commensal pathogens to monocolonized by *H. pylori* germ-free insulin-gastrin (INS-GAS) transgenic mouse models' stomach there was a progressive advancement to gastric neoplastic lesions.

Viewing the aforementioned data, while a role for *H. pylori* in gastric oncogenesis cannot be doubted, emerging data shows that additional bacteria in the GM also seem to be involved in the transformation of stomach epithelial cells[74]. Nevertheless, whether it is the *Hp*-I that stimulates growth of unwanted bacteria or *vice versa* warrants clarification.

In a survey, Jo *et al*[75] showed that in GC patients, the records of nitrosating/nitrate-reducing microbes other than *H. pylori* were no less than doubled in comparison with healthy controls exhibiting similar *H. pylori* status, albeit insignificantly. Thus, further basic research is necessary to illuminate whether GM alterations are crucial to GC development or are the result of alterations in the gastric setting.

Microbial infections have been incriminated for a variety of cancers by transforming host cells and triggering neoplastic characters and inflammatory reactions, disrupting cell configuration and altering their genomes. Therefore, it is rational to consider the possible role of the intestinal microbiota in gastric oncogenesis[76]. Furthermore, under the consideration that *H. pylori* plays a dominant role in Correa's cascade (*i.e.*, from NAG to atrophic gastritis and further to IM, dysplasia and GC), the inflammatory process of gastritis could be considered to be started and continued by *Hp*-I, which can colonize epithelium decades before neoplastic transformation. Ultimately, this transformation could develop owing to augmented pH of the stomach because of the loss of parietal cells and the multiplication of microbes other than *H. pylori*[18]. Certainly, the microbiota differs between patients with chronic gastritis, IM and GC. The later indicates the significant role of gut microbiota in *H. pylori*-related tumorigenic effect. In contrast, progressive alterations in gastric pH could also be anticipated through *H. pylori*-derived histological alterations, facilitating the gastric colonization from other bacteria[18]. Other investigators showed that the GC microbiota mainly included *Citrobacter*, *Achromobacter*, *Clostridium*, *Lactobacillus*, *Phyllobacterium* and *Rhodococcus*. Nevertheless, additional research is warranted to clarify the fingerprint of bacterial populations associated with gastric disorders in connection with the Correa's cascade sequence.

Currently, the comprehension of dysbiosis-related genotoxicity and inflammation needs to move from descriptive studies to functionally based studies which investigate the effects of specific taxa and bacteria-derived metabolites on the gastric mucosa. In this regard, the potential introduction of probiotics should be studied thoroughly in order to delineate its effectiveness in the rebalance of human microbiota synthesis[77].



DOI: 10.4251/wjgo.v14.i5.959 Copyright ©The Author(s) 2022.

**Figure 2 Gastric microbial composition in the healthy and diseased stomach.** Under normal healthy conditions without evidence of excessive inflammation, *Helicobacter pylori* (*H. pylori*) exists in very low abundance. On the contrary, in chronic gastritis, *H. pylori* is the predominant bacteria with the presence of other microorganisms as well but at lower rates. However, as the sequelae of carcinogenesis moves towards malignancy, oral or intestinal-type pathogens exclusively predominate.

## INTERACTION BETWEEN *HP-I*, GASTRIC MICROBIOTA AND GASTRIC CANCER

The perpetuation of *Hp-I* reduces microbiota diversity and is connected with atrophy, IM and GC[78]. Although it represents the main genus in chronic gastritis with a mean relative abundance of 42% (varying from 0.01%-95%), *H. pylori* presents a dramatic decrease in GC tissues with a relative abundance of 6%. In this regard, recent data based on RNA sequencing analyses revealed that *H. pylori* entirely dominated the microbiota not only in infected patients but also in the majority of individuals categorized as *H. pylori*-uninfected using conventional approaches, thus implying an active role in all cases of GC development[78].

The vast majority of information regarding the role of GM in carcinogenesis derives from preclinical studies in INS-GAS transgenic mouse models. Complex microbiota has been associated with intensive gastric inflammation, epithelial damage, oxyntic gland atrophy, hyperplasia, metaplasia and dysplasia [71]. Moreover, co-infection with *H. pylori* in INS-GAS rodents predisposed to more severe gastric lesions and earlier development of early GC in comparison to *H. pylori*-infected germ-free INS-GAS mice[71]. Concerning the co-infective bacteria, complex microbiota and restricted microbiota consisting of only three species of commensal murine bacteria (*Clostridium* sp., *Lactobacillus murinus* and *Bacteroides* sp.) predisposed similarly to neoplasia generation in *H. pylori* positive models[73]. Further *in vivo* studies with *Hp-I* revealed that the co-infection with commensal microbiota accelerated the progression to gastric intraepithelial neoplasia and the progression to cancer, whereas the treatment with antibiotics delayed the gastric tumorigenesis in *H. pylori*-free and specific pathogen-free INS-GAS mice[73,79,80]. Moreover, the environment of gastric atrophy reduces the density of *H. pylori* aggregates to give rise to bacteria from other locations of the GIT, thus perpetuating the inflammatory process and genotoxicity, to induce malignant transformation. The overgrowth of such microbiome could partially contribute to the “point of no return” of carcinogenesis prevention after *H. pylori* eradication[81]. As already known, eradication of *H. pylori* is associated with a reduced risk of GC, although ambiguity exists over whether this is an isolated result from the eradication of the *H. pylori* or the modification of the whole GM, as bacterial diversity increases probably beneficially[80].

Interestingly, Eun *et al*[82] reported variations in the composition and diversity of GM among patients with chronic gastritis, IM and GC. More specifically, in the early stages of carcinogenesis, *H. pylori* may trigger the development of CAG, rather than direct induction of GC[82]. Subsequently, the resulting increased pH provokes changes in the constitution of GM thus facilitating the progression from CAG to IM and finally to GC[83]. On the other hand, subjects with GC showed a significant increase in the *Bacilli* class and *Streptococcaceae* family whereas the *Epsilonproteobacteria* class and *Helicobacteriaceae* family were decreased[82]. As suggested by Correa *et al*[84], chronic *Hp-I* triggers a CAG with the mentioned defective acid secretion, thus facilitating the excessive colonization of gastric microflora with bacteria capable of reducing nitrate to nitrite, to form N-nitroso compounds that are carcinogenic[84,85]. In this regard, the GC microbiome is different from atrophic gastritis and possesses increased representation of nitrate reductases, with *Citrobacter*, *Achromobacter*, *Clostridium*, *Campylobacter*,

*Deinococcus*, *Sulfurospirillum* and *Phyllobacterium* representing ascendant species[79], thus accelerating the development of GC following *Hp*-I in INS-GAS mice when compared to germ-free mice that were monocolonized by *H. pylori*[71]. Relatively, chronic treatment with the mentioned PPIs increases the potential of atrophy among *H. pylori* positive subjects[86] in contrast to *H. pylori* negative individuals or patients receiving eradication treatment thus implying that the non-*H. pylori* microbiota could only promote gastric atrophy when co-existing with *H. pylori*[35,87].

The activity of gastritis is well known for its close relationship with *Hp*-I. A similar motif of diversity is suggested for further phyla, such as *Bacteroidetes* and increased abundances of *Firmicutes* or *Proteobacteria*, thus incriminating their dysbiosis for gastric carcinogenesis[87]. Nevertheless, despite the wide range of studies associating *Hp*-I with gastric dysbiosis, no data interpret the exact background of this interaction which seems to promote a sustained inflammation and genotoxicity[88]. A widely acceptable pattern suggests that chronic gastric inflammatory response to *H. pylori* may modify the gastric environment, paving the way to the growth of a dysbiotic gastric bacterial community; and *H. pylori* eradication reverses the gastric dysbiosis to a similar level to uninfected patients, and exerts beneficial effects on gut microbiota, achieving an increased probiotic and putative downregulation of drug-resistance[89]. More specifically, successful *H. pylori* eradication inhibited dysbiosis significantly ( $P < 0.001$ ), although it remained higher than that of the *H. pylori* negative arm ( $P = 0.025$ ). Nonetheless, treatment failure was associated with increased dysbiosis rate comparable to active *Hp*-I ( $P = 0.351$ )[89]. Intense dysbiosis was further found to be analogous to the progress from gastritis to atrophy, IM and GC (both  $P < 0.001$ )[89].

Pathophysiologically, the highly expressed VacA (vacuolating cytotoxin A), after *Hp*-I, binds to the receptor proteins tyrosine phosphatase  $\alpha$  and  $\beta$  on gastric cells, thus generating pores to yield bacterial internalization[90]. Some data indicated that antibodies against VacA could be correlated with both peptic ulcer and gastric malignant disorders, thus it could be considered as a biomarker of both pathologies[91]. Additionally, *H. pylori* survival promoted by VacA is independent of CagA (cytotoxin-associated gene A) accumulation. VacA is connected with mucolipin 1 (transient receptor channel) which impedes the death of microbial cells through autophagic procedure and permits the formation of an intracellular niche in which *H. pylori* survives[91]. In this regard, infection of the AGS gastric adenocarcinoma cell line with *H. pylori* for 6 h, lead to autophagy that was dependent on VacA[92]. This implied that autophagy is activated by cells infected by *H. pylori* to evade the destructive effects of toxins thus promoting cell survival. In addition, others reported that 1 d exposure to VacA disturbs the antiphagocytic signaling and accumulates defective autophagosomes in cells[92]. Likewise, *H. pylori* controls the autophagocytic pathway as well as the expression of genes related to autophagy in both macrophages and gastric epithelial cells[93]. Therefore, it appears that during the initiation of carcinogenesis, the aforementioned pathway has a regulatory role and when suppressed, leads to premalignant disorders, induces oxidative stress, promotes cell growth, penetration and eventually metastases. Concerning GC, this could lead to precursor lesions extension[93]. Interestingly, there is a direct association between pathogens that induce dysbiosis and disturbed immune responses including apoptosis - autophagy and orodigestive cancers, including GC[93].

Besides, *H. pylori* releases a plethora of adhesins (BabA, BabB, SabA, AlpA and AlpB) which facilitate the opening of tight junctions (TJ) and adherent junctions (AJ)[94-96]. In this regard, *in vivo* CagA causes depolarization and disruption of the TJ barrier function in epithelial cells to the *H. pylori* attachment sites[7,94]. Additionally, after *in vitro* excessive administration, CagA binds to membrane e-cadherins, inhibits their interaction with  $\beta$ -catenin to disrupt the AJs' integrity and tightness[97]. *In vivo* cagA with *Lactobacillus* enhances the effect of *H. pylori* to human monocyte-derived dendritic cells (DC) leading to DC maturation and induction, beyond *H. pylori*, additional inflammatory mediators[93]. This implies that the bacteria that produce lactic acid could increase *H. pylori* related inflammation promoting gastric oncogenesis. The latter are in concordance with human GM studies displaying a plethora of *Lactobacillus* in *H. pylori*-connected IM and GC (intestinal type) vs NAG[62] and the increased *Lactobacillus* in INS-GAS mouse model studies infected with *H. pylori* and reduced commensals (*Clostridium*, *Lactobacillus*, and *Bacteroides*) which develop gastric intraepithelial neoplasia[73]. Nevertheless, other findings indicate a probiotic *Lactobacillus* strain that inhibits *H. pylori* colonization in a Mongolian gerbil model [98]. More relevant to biofilm-associated *H. pylori*, *Streptococcus mitis* interacts with *H. pylori* in co-culture studies, converting it to coccoid cells, as proteomic analysis reveals, signifying an apparent impact on gastric oncogenesis linked with *H. pylori*[99,100]. Moreover, experimental data on INS-GAS mice co-colonized with *H. pylori* and *Streptococcus Salivarius* showed more severe gastritis when compared with solely *Hp*-I only at 5 mo post-infection. The latter data signify strong interactions among several bacteria and *H. pylori* that in turn may affect *H. pylori*-related tumorigenesis[101]. Of note, *H. pylori*-induced biofilms are associated with resistance to *H. pylori* antibiotic eradication regimens[102]; *H. pylori* biofilms appear to be one of the main barriers to *H. pylori* eradication, by inhibiting antibiotics penetration and augmenting the expression of efflux pumps and mutations, several therapeutic failures and chronic infections[103].

Finally, the interplay between *H. pylori* and GM in the pathogenesis of GC can be dependent on Toll-like receptors through a perpetual stimulation by *H. pylori* and potentially by other microorganisms [104]. In this regard, *Hp*-I seems to create a premalignant environment of atrophy and IM and the subsequent alterations in GM in later stages play a more relevant role in carcinogenesis itself[105].



## CONCLUSION

It is more than clear that *Hp*-I, GM and GC constitute a challenging tangle due to the strong interaction between them making it difficult to unroll it.

The stomach harbors a large and diverse bacterial community with *H. pylori*, a member of Proteobacteria phylum, being the most dominant and abundant genus. The main phyla colonizing the stomach are Proteobacteria, Bacteroidetes, Firmicutes, Fusobacteria and Actinobacteria. Most studies show that *H. pylori* has inhibitory effects on the colonization of other bacteria, harboring a lower diversity of them in the stomach. Other factors that influence GM are dietary habits, age, ethnicity, medication use (PPIs, antibiotics), gastric mucosa inflammation and GC. It is worthwhile to mention that GM differs in patients with chronic gastritis, IM, dysplasia or GC, but its role in GC has not yet been fully elucidated. Data shows that from a specific point and beyond, apart from *H. pylori*-related gastritis, the GC progress seems not to be related with *H. pylori* presence, since the gastric adenocarcinoma microbiota mainly consists of intestinal and oral bacterial genera, considering that this progression can happen even after successful *H. pylori* eradication. The above has been verified to an accountable level by well-designed animal model experiments. In accordance, beyond *H. pylori*'s role in gastric oncogenesis, other bacteria, *H. pylori*-stimulated or not, in GM also seem to be responsible for transformation of gastric epithelial cells.

To conclude, the aforementioned studies amongst others have begun to shed light into the maze of GC complex pathogenesis where abundant data show that beyond *H. pylori* related gastritis, additional pathogens might contribute to this type of cancer development. Nevertheless, large-scale experiments are needed to discern the exact role of different kinds of pathogens which reside in the stomach and their contribution to neoplasia emergence, aiding in the prediction of adverse prognosis of a specific microbiota diversity. Only then would the manipulation of GM be feasible, modifying the number and the types of the necessary commensals.

## FOOTNOTES

**Author contributions:** Liatsos C conceived the idea, provided revisions to the scientific manuscript content and participated in the writing, corrections and completion of all stages of the manuscript; Papaefthymiou A, Kyriakos N, Galanopoulos M, Doulberis M and Giakoumis M participated in manuscript writing and literature data finding; Petridou E contributed to literature data finding and editing; Mavrogiannis C, Rokkas T and Papaefthymiou A provided revisions and editing of the manuscript; Kountouras J participated in the writing, reviewing and final editing of the manuscript.

**Conflict-of-interest statement:** The authors declare having no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** Greece

**ORCID number:** Christos Liatsos 0000-0001-8025-0808; Apostolis Papaefthymiou 0000-0002-3563-4973; Nikolaos Kyriakos 0000-0002-7395-6594; Michail Galanopoulos 0000-0002-7544-2810; Michael Doulberis 0000-0002-0396-5081; Marios Giakoumis 0000-0002-9909-5454; Evangelia Petridou 0000-0002-4926-4408; Christos Mavrogiannis 0000-0001-6163-5884; Theodore Rokkas 0000-0001-6475-3026; Jannis Kountouras 0000-0001-6459-5136.

**S-Editor:** Chang KL

**L-Editor:** Filipodia

**P-Editor:** Chang KL

## REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]
- Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology* 2017; **153**: 420-429 [PMID: 28456631 DOI: 10.1053/j.gastro.2017.04.022]
- de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol* 2012; **13**: 607-615 [PMID: 22575588 DOI: 10.1016/S1473-3099(12)70133-2]

- 10.1016/S1470-2045(12)70137-7]
- 4 **Cheung KS**, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. *Therap Adv Gastroenterol* 2019; **12**: 1756284819834511 [PMID: 30886648 DOI: 10.1177/1756284819834511]
- 5 **Liatsos C**, Rokkas T. The Effect of Chronic Use of Proton Pump Inhibitors on Gastric Cancer: Should We Be Aware of It? *Dig Dis* 2018; **36**: 395-396 [PMID: 29874647 DOI: 10.1159/000489629]
- 6 **Moss SF**. The Clinical Evidence Linking *Helicobacter pylori* to Gastric Cancer. *Cell Mol Gastroenterol Hepatol* 2017; **3**: 183-191 [PMID: 28275685 DOI: 10.1016/j.jcmgh.2016.12.001]
- 7 **Amieva MR**, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. *Science* 2003; **300**: 1430-1434 [PMID: 12775840 DOI: 10.1053/j.gastro.2015.09.004]
- 8 **Kountouras J**, Kapetanakis N, Zavos C, Polyzos SA, Romiopoulou I, Tsiaousi E, Anastasiadou K, Giorgakis N, Vardaka E, Nikolaidou C, Venizelos I, Katsinelos P. *Helicobacter pylori* might contribute to cancer and/or bone marrow-derived stem cell-related gastrointestinal oncogenesis. *Oncogene* 2015; **34**: 670 [PMID: 24469039 DOI: 10.1038/onc.2013.602]
- 9 **Babu SD**, Jayanthi V, Devaraj N, Reis CA, Devaraj H. Expression profile of mucins (MUC2, MUC5AC and MUC6) in *Helicobacter pylori* infected pre-neoplastic and neoplastic human gastric epithelium. *Mol Cancer* 2006; **5**: 10 [PMID: 16545139 DOI: 10.1186/1476-4598-5-10]
- 10 **Kountouras J**, Doulberis M, Papaefthymiou A, Polyzos SA, Vardaka E, Tzivras D, Dardiotis E, Deretzi G, Giartza-Taxidou E, Grigoriadis S, Katsinelos P. A perspective on risk factors for esophageal adenocarcinoma: emphasis on *Helicobacter pylori* infection. *Ann N Y Acad Sci* 2019; **1452**: 12-17 [PMID: 31310338 DOI: 10.1111/nyas.14168]
- 11 **Zhang S**, Shi D, Li M, Li Y, Wang X, Li W. The relationship between gastric microbiota and gastric disease. *Scand J Gastroenterol* 2019; **54**: 391-396 [PMID: 30945954 DOI: 10.1080/00365521.2019.1591499]
- 12 **Burkitt MD**, Duckworth CA, Williams JM, Pritchard DM. *Helicobacter pylori*-induced gastric pathology: insights from *in vivo* and *ex vivo* models. *Dis Model Mech* 2017; **10**: 89-104 [PMID: 28151409 DOI: 10.1242/dmm.027649]
- 13 **Yuan G**, Chen Y, He S. Family History of Gastric Cancer and *Helicobacter pylori* Treatment. *N Engl J Med* 2020; **382**: 2171 [PMID: 32459942 DOI: 10.1056/NEJMc2003542]
- 14 **Chooi YC**, Ding C, Magkos F. The epidemiology of obesity. *Metabolism* 2019; **92**: 6-10 [PMID: 30253139 DOI: 10.1016/j.metabol.2018.09.005]
- 15 **Choi IJ**, Kim CG, Lee JY, Kim YI, Kook MC, Park B, Joo J. Family History of Gastric Cancer and *Helicobacter pylori* Treatment. *N Engl J Med* 2020; **382**: 427-436 [PMID: 31995688 DOI: 10.1056/NEJMoa1909666]
- 16 **Choi IJ**, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH. *Helicobacter pylori* Therapy for the Prevention of Metachronous Gastric Cancer. *N Engl J Med* 2018; **378**: 1085-1095 [PMID: 29562147 DOI: 10.1056/NEJMoa1708423]
- 17 **Díaz P**, Valenzuela Valderrama M, Bravo J, Quest AFG. *Helicobacter pylori* and Gastric Cancer: Adaptive Cellular Mechanisms Involved in Disease Progression. *Front Microbiol* 2018; **9**: 5 [PMID: 29403459 DOI: 10.3389/fmicb.2018.00005]
- 18 **Alarcón T**, Llorca L, Perez-Perez G. Impact of the Microbiota and Gastric Disease Development by *Helicobacter pylori*. *Curr Top Microbiol Immunol* 2017; **400**: 253-275 [PMID: 28124157 DOI: 10.1007/978-3-319-50520-6\_11]
- 19 **Kountouras J**, Boziki M, Polyzos SA, Katsinelos P, Gavalas E, Zeglinas C, Tzivras D, Romiopoulou I, Giorgakis N, Anastasiadou K, Vardaka E, Kountouras C, Kazakos E, Giartza-Taxidou E, Deretzi G, Dardiotis E, Kotronis G, Doulberis M. The Emerging Role of *Helicobacter Pylori*-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. *Curr Mol Med* 2017; **17**: 389-404 [PMID: 29256351 DOI: 10.2174/1566524018666171219094837]
- 20 **Kountouras J**, Polyzos SA, Doulberis M, Zeglinas C, Artemaki F, Vardaka E, Deretzi G, Giartza-Taxidou E, Tzivras D, Vlachaki E, Kazakos E, Katsinelos P, Mantzoros CS. Potential impact of *Helicobacter pylori*-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. *Metabolism* 2018; **87**: 18-24 [PMID: 29936174 DOI: 10.1016/j.metabol.2018.06.008]
- 21 **Saetang J**, Sangkhathat S. Diets link metabolic syndrome and colorectal cancer development (Review). *Oncol Rep* 2017; **37**: 1312-1320 [PMID: 28098913 DOI: 10.3892/or.2017.5385]
- 22 **Schulz C**, Koch N, Schütte K, Pieper DH, Malferttheiner P. H. *pylori* and its modulation of gastrointestinal microbiota. *J Dig Dis* 2015; **16**: 109-117 [PMID: 25624012 DOI: 10.1111/1751-2980.12233]
- 23 **Sgambato D**, Miranda A, Romano L, Romano M. Gut microbiota and gastric disease. *Minerva Gastroenterol Dietol* 2017; **63**: 345-354 [PMID: 28206729 DOI: 10.23736/S1121-421X.17.02380-7]
- 24 **Wang L**, Peng F, Peng C, Du JR. Gut Microbiota in Tumor Microenvironment: A Critical Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine. *Am J Chin Med* 2021; **49**: 609-626 [PMID: 33683187 DOI: 10.1142/S0192415X21500270]
- 25 **Sheh A**, Fox JG. The role of the gastrointestinal microbiome in *Helicobacter pylori* pathogenesis. *Gut Microbes* 2013; **4**: 505-531 [PMID: 23962822 DOI: 10.4161/gmic.26205]
- 26 **Wroblewski LE**, Peek RM Jr, Wilson KT. *Helicobacter pylori* and gastric cancer: factors that modulate disease risk. *Clin Microbiol Rev* 2010; **23**: 713-739 [PMID: 20930071 DOI: 10.1128/CMR.00011-10]
- 27 **Sanduleanu S**, Jonkers D, De Bruine A, Hameeteman W, Stockbrügger RW. Non-*Helicobacter pylori* bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. *Aliment Pharmacol Ther* 2001; **15**: 379-388 [PMID: 11207513 DOI: 10.1046/j.1365-2036.2001.00888.x]
- 28 **Yu G**, Torres J, Hu N, Medrano-Guzman R, Herrera-Goepfert R, Humphrys MS, Wang L, Wang C, Ding T, Ravel J, Taylor PR, Abnet CC, Goldstein AM. Molecular Characterization of the Human Stomach Microbiota in Gastric Cancer Patients. *Front Cell Infect Microbiol* 2017; **7**: 302 [PMID: 28730144 DOI: 10.3389/fcimb.2017.00302]
- 29 **Harris PR**, Smythies LE, Smith PD, Perez-Perez GI. Role of childhood infection in the sequelae of H. *pylori* disease. *Gut Microbes* 2013; **4**: 426-438 [PMID: 24275060 DOI: 10.4161/gmic.26943]
- 30 **Savage DC**. Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol* 1977; **31**: 107-133 [PMID: 334036 DOI: 10.1146/annurev.mi.31.100177.000543]
- 31 **Adamsson I**, Nord CE, Lundquist P, Sjöstedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus



- metronidazole vs omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. *J Antimicrob Chemother* 1999; **44**: 629-640 [PMID: 10552979 DOI: 10.1093/jac/44.5.629]
- 32 Schulz C, Schütte K, Malfertheiner P. Helicobacter pylori and Other Gastric Microbiota in Gastroduodenal Pathologies. *Dig Dis* 2016; **34**: 210-216 [PMID: 27028228 DOI: 10.1159/000443353]
  - 33 Yang I, Woltemate S, Piazuolo MB, Bravo LE, Yepez MC, Romero-Gallo J, Delgado AG, Wilson KT, Peek RM, Correa P, Josenhans C, Fox JG, Suerbaum S. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. *Sci Rep* 2016; **6**: 18594 [PMID: 26729566 DOI: 10.1038/srep18594]
  - 34 Hu Y, He LH, Xiao D, Liu GD, Gu YX, Tao XX, Zhang JZ. Bacterial flora concurrent with Helicobacter pylori in the stomach of patients with upper gastrointestinal diseases. *World J Gastroenterol* 2012; **18**: 1257-1261 [PMID: 22468090 DOI: 10.3748/wjg.v18.i11.1257]
  - 35 Engstrand L, Lindberg M. Helicobacter pylori and the gastric microbiota. *Best Pract Res Clin Gastroenterol* 2013; **27**: 39-45 [PMID: 23768551 DOI: 10.1016/j.bpg.2013.03.016]
  - 36 Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, Perez-Perez G, Blaser MJ, Relman DA. Molecular analysis of the bacterial microbiota in the human stomach. *Proc Natl Acad Sci U S A* 2006; **103**: 732-737 [PMID: 16407106 DOI: 10.1073/pnas.0506655103]
  - 37 Sung J, Kim N, Kim J, Jo HJ, Park JH, Nam RH, Seok YJ, Kim YR, Lee DH, Jung HC. Comparison of Gastric Microbiota Between Gastric Juice and Mucosa by Next Generation Sequencing Method. *J Cancer Prev* 2016; **21**: 60-65 [PMID: 27051651 DOI: 10.15430/JCP.2016.21.1.60]
  - 38 Zilberstein B, Quintanilha AG, Santos MA, Pajecski D, Moura EG, Alves PR, Maluf Filho F, de Souza JA, Gama-Rodrigues J. Digestive tract microbiota in healthy volunteers. *Clinics (Sao Paulo)* 2007; **62**: 47-54 [PMID: 17334549 DOI: 10.1590/S1807-59322007000100008]
  - 39 Katsinelos T, Doulberis M, Polyzos SA, Papaefthymiou A, Katsinelos P, Kountouras J. Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement. *Curr Mol Med* 2019; **20**: 3-12 [PMID: 31530263 DOI: 10.2174/1566524019666190917125917]
  - 40 Parsons BN, Ijaz UZ, D'Amore R, Burkitt MD, Eccles R, Lenzi L, Duckworth CA, Moore AR, Tiszlavicz L, Varro A, Hall N, Pritchard DM. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. *PLoS Pathog* 2017; **13**: e1006653 [PMID: 29095917 DOI: 10.1371/journal.ppat.1006653]
  - 41 Espinoza JL, Matsumoto A, Tanaka H, Matsumura I. Gastric microbiota: An emerging player in Helicobacter pylori-induced gastric malignancies. *Cancer Lett* 2018; **414**: 147-152 [PMID: 29138097 DOI: 10.1016/j.canlet.2017.11.009]
  - 42 Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. *PLoS One* 2008; **3**: e2836 [PMID: 18665274 DOI: 10.1371/journal.pone.0002836]
  - 43 Llorca L, Pérez-Pérez G, Urruzuno P, Martínez MJ, Iizumi T, Gao Z, Sohn J, Chung J, Cox L, Simón-Soro A, Mira A, Alarcón T. Characterization of the Gastric Microbiota in a Pediatric Population According to Helicobacter pylori Status. *Pediatr Infect Dis J* 2017; **36**: 173-178 [PMID: 27820723 DOI: 10.1097/INF.0000000000001383]
  - 44 Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, Karaaz U, Contreras M, Blaser MJ, Brodie EL, Dominguez-Bello MG. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. *ISME J* 2011; **5**: 574-579 [PMID: 20927139 DOI: 10.1038/ismej.2010.149]
  - 45 Shannon CE. A Mathematical Theory of Communication. *Bell Syst Tech J* 1948; **27**: 379-423 [DOI: 10.1002/j.1538-7305.1948.tb01338.x]
  - 46 Simpson EH. Measurement of Diversity. *Nature* 1949; **163**: 688-688 [DOI: 10.1038/163688a0]
  - 47 Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, Uchida T, Yamaoka Y. Gastric Microbiota in Helicobacter pylori-Negative and -Positive Gastritis Among High Incidence of Gastric Cancer Area. *Cancers (Basel)* 2019; **11** [PMID: 30974798 DOI: 10.3390/cancers11040504]
  - 48 Miao R, Wan C, Wang Z. The relationship of gastric microbiota and Helicobacter pylori infection in pediatrics population. *Helicobacter* 2020; **25**: e12676 [PMID: 31762120 DOI: 10.1111/hel.12676]
  - 49 Wroblewski LE, Peek RM Jr. Helicobacter pylori, Cancer, and the Gastric Microbiota. *Adv Exp Med Biol* 2016; **908**: 393-408 [PMID: 27573782 DOI: 10.1007/978-3-319-41388-4\_19]
  - 50 Chan YK, Estaki M, Gibson DL. Clinical consequences of diet-induced dysbiosis. *Ann Nutr Metab* 2013; **63** Suppl 2: 28-40 [PMID: 24217034 DOI: 10.1159/000354902]
  - 51 Fan W, Huo G, Li X, Yang L, Duan C. Impact of diet in shaping gut microbiota revealed by a comparative study in infants during the six months of life. *J Microbiol Biotechnol* 2014; **24**: 133-143 [PMID: 24169452 DOI: 10.4014/jmb.1309.09029]
  - 52 Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. *J Gastroenterol* 2014; **49**: 785-798 [PMID: 24652102 DOI: 10.1007/s00535-014-0953-z]
  - 53 David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014; **505**: 559-563 [PMID: 24336217 DOI: 10.1038/nature12820]
  - 54 Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, Tsuchiya S, Okayama T, Dohi O, Yoshida N, Kamada K, Ishikawa T, Handa O, Konishi H, Okuda K, Tsujimoto Y, Ohnogi H, Itoh Y. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. *J Clin Biochem Nutr* 2018; **62**: 100-105 [PMID: 29371761 DOI: 10.3164/jcbs.17-78]
  - 55 Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 483-490 [PMID: 23270866 DOI: 10.1016/j.cgh.2012.12.011]
  - 56 Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. *Curr Drug Metab* 2009; **10**: 84-89 [PMID: 19149516 DOI: 10.2174/138920009787048392]

- 57 **Paroni Sterbini F**, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, Bugli F, Martini C, Ricciardi W, Gasbarrini A, Sanguinetti M, Cammarota G, Posteraro B. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. *Appl Environ Microbiol* 2016; **82**: 6633-6644 [PMID: [27590821](#) DOI: [10.1128/AEM.01437-16](#)]
- 58 **Malfetheriner P**, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 697-710 [PMID: [28930292](#) DOI: [10.1038/nrgastro.2017.117](#)]
- 59 **Mason KL**, Erb Downward JR, Falkowski NR, Young VB, Kao JY, Huffnagle GB. Interplay between the gastric bacterial microbiota and *Candida albicans* during postantibiotic recolonization and gastritis. *Infect Immun* 2012; **80**: 150-158 [PMID: [21986629](#) DOI: [10.1128/IAI.05162-11](#)]
- 60 **Aviles-Jimenez F**, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. *Sci Rep* 2014; **4**: 4202 [PMID: [24569566](#) DOI: [10.1038/srep04202](#)]
- 61 **Noto JM**, Peek RM Jr. The gastric microbiome, its interaction with *Helicobacter pylori*, and its potential role in the progression to stomach cancer. *PLoS Pathog* 2017; **13**: e1006573 [PMID: [28982167](#) DOI: [10.1371/journal.ppat.1006573](#)]
- 62 **Coker OO**, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JY, Yu J. Mucosal microbiome dysbiosis in gastric carcinogenesis. *Gut* 2018; **67**: 1024-1032 [PMID: [28765474](#) DOI: [10.1136/gutjnl-2017-314281](#)]
- 63 **Brusselsaers N**, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. *BMJ Open* 2017; **7**: e017739 [PMID: [29084798](#) DOI: [10.1136/bmjopen-2017-017739](#)]
- 64 **Song H**, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. *Cochrane Database Syst Rev* 2014; CD010623 [PMID: [25464111](#) DOI: [10.1002/14651858.CD010623.pub2](#)]
- 65 **Eslami L**, Nasser-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? *Arch Iran Med* 2013; **16**: 449-458 [PMID: [23906249](#)]
- 66 **Vogiatzi P**, Cassone M, Luzzi I, Lucchetti C, Otvos L Jr, Giordano A. *Helicobacter pylori* as a class I carcinogen: physiopathology and management strategies. *J Cell Biochem* 2007; **102**: 264-273 [PMID: [17486575](#) DOI: [10.1002/jcb.21375](#)]
- 67 **Rajilic-Stojanovic M**, Figueiredo C, Smet A, Hansen R, Kupcinskas J, Rokkas T, Andersen L, Machado JC, Ianiro G, Gasbarrini A, Leja M, Gisbert JP, Hold GL. Systematic review: gastric microbiota in health and disease. *Aliment Pharmacol Ther* 2020; **51**: 582-602 [PMID: [32056247](#) DOI: [10.1111/apt.15650](#)]
- 68 **Vogtmann E**, Goedert JJ. Epidemiologic studies of the human microbiome and cancer. *Br J Cancer* 2016; **114**: 237-242 [PMID: [26730578](#) DOI: [10.1038/bjc.2015.465](#)]
- 69 **Dicksved J**, Lindberg M, Rosenquist M, Enroth H, Jansson JK, Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. *J Med Microbiol* 2009; **58**: 509-516 [PMID: [19273648](#) DOI: [10.1099/jmm.0.007302-0](#)]
- 70 **Robinson KM**, Crabtree J, Mattick JS, Anderson KE, Dunning Hotopp JC. Distinguishing potential bacteria-tumor associations from contamination in a secondary data analysis of public cancer genome sequence data. *Microbiome* 2017; **5**: 9 [PMID: [28118849](#) DOI: [10.1186/s40168-016-0224-8](#)]
- 71 **Lofgren JL**, Whary MT, Ge Z, Muthupalani S, Taylor NS, Mobley M, Potter A, Varro A, Eibach D, Suerbaum S, Wang TC, Fox JG. Lack of commensal flora in *Helicobacter pylori*-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. *Gastroenterology* 2011; **140**: 210-220 [PMID: [20950613](#) DOI: [10.1053/j.gastro.2010.09.048](#)]
- 72 **Rolig AS**, Cech C, Ahler E, Carter JE, Ottemann KM. The degree of *Helicobacter pylori*-triggered inflammation is manipulated by preinfection host microbiota. *Infect Immun* 2013; **81**: 1382-1389 [PMID: [23429529](#) DOI: [10.1128/IAI.00044-13](#)]
- 73 **Lertpiriyapong K**, Whary MT, Muthupalani S, Lofgren JL, Gamazon ER, Feng Y, Ge Z, Wang TC, Fox JG. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the *Helicobacter pylori* INS-GAS mouse model of gastric carcinogenesis. *Gut* 2014; **63**: 54-63 [PMID: [23812323](#) DOI: [10.1136/gutjnl-2013-305178](#)]
- 74 **Liu X**, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L, Ling Z. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. *EBioMedicine* 2019; **40**: 336-348 [PMID: [30584008](#) DOI: [10.1016/j.ebiom.2018.12.034](#)]
- 75 **Jo HJ**, Kim J, Kim N, Park JH, Nam RH, Seok YJ, Kim YR, Kim JS, Kim JM, Lee DH, Jung HC. Analysis of Gastric Microbiota by Pyrosequencing: Minor Role of Bacteria Other Than *Helicobacter pylori* in the Gastric Carcinogenesis. *Helicobacter* 2016; **21**: 364-374 [PMID: [26915731](#) DOI: [10.1111/hel.12293](#)]
- 76 **Eyvazi S**, Vostakolaei MA, Dilmaghani A, Borumandi O, Hejazi MS, Kahroba H, Tarhriz V. The oncogenic roles of bacterial infections in development of cancer. *Microb Pathog* 2020; **141**: 104019 [PMID: [32006638](#) DOI: [10.1016/j.micpath.2020.104019](#)]
- 77 **Homan M**, Orel R. Are probiotics useful in *Helicobacter pylori* eradication? *World J Gastroenterol* 2015; **21**: 10644-10653 [PMID: [26457024](#) DOI: [10.3748/wjg.v21.i37.10644](#)]
- 78 **Li TH**, Qin Y, Sham PC, Lau KS, Chu KM, Leung WK. Alterations in Gastric Microbiota After *H. Pylori* Eradication and in Different Histological Stages of Gastric Carcinogenesis. *Sci Rep* 2017; **7**: 44935 [PMID: [28322295](#) DOI: [10.1038/srep44935](#)]
- 79 **Thorell K**, Bengtsson-Palme J, Liu OH, Palacios Gonzales RV, Nookaew I, Rabeneck L, Paszat L, Graham DY, Nielsen J, Lundin SB, Sjöling Å. *In Vivo* Analysis of the Viable Microbiota and *Helicobacter pylori* Transcriptome in Gastric Infection and Early Stages of Carcinogenesis. *Infect Immun* 2017; **85** [PMID: [28694295](#) DOI: [10.1128/IAI.00031-17](#)]
- 80 **Lee CW**, Rickman B, Rogers AB, Muthupalani S, Takaishi S, Yang P, Wang TC, Fox JG. Combination of sulindac and antimicrobial eradication of *Helicobacter pylori* prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. *Cancer Res* 2009; **69**: 8166-8174 [PMID: [19826057](#) DOI: [10.1158/0008-5472.CAN-08-3856](#)]
- 81 **Mera RM**, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, Yopez MC, Realpe JL, Schneider BG, Morgan DR, Peek RM Jr, Correa P, Wilson KT, Piazuelo MB. Dynamics of *Helicobacter pylori* infection as a determinant

- of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. *Gut* 2018; **67**: 1239-1246 [PMID: 28647684 DOI: 10.1136/gutjnl-2016-311685]
- 82 **Eun CS**, Kim BK, Han DS, Kim SY, Kim KM, Choi BY, Song KS, Kim YS, Kim JF. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. *Helicobacter* 2014; **19**: 407-416 [PMID: 25052961 DOI: 10.1111/hel.12145]
  - 83 **Dias-Jácome E**, Libânio D, Borges-Canha M, Gallagher A, Pimentel-Nunes P. Gastric microbiota and carcinogenesis: the role of non-*Helicobacter pylori* bacteria - A systematic review. *Rev Esp Enferm Dig* 2016; **108**: 530-540 [PMID: 27604361 DOI: 10.17235/reed.2016.4261/2016]
  - 84 **Correa P**, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. *Lancet* 1975; **2**: 58-60 [PMID: 49653 DOI: 10.1016/s0140-6736(75)90498-5]
  - 85 **Plottel CS**, Blaser MJ. Microbiome and malignancy. *Cell Host Microbe* 2011; **10**: 324-335 [PMID: 22018233 DOI: 10.1016/j.chom.2011.10.003]
  - 86 **Naylor G**, Axon A. Role of bacterial overgrowth in the stomach as an additional risk factor for gastritis. *Can J Gastroenterol* 2003; **17** Suppl B: 13B-17B [PMID: 12845343 DOI: 10.1155/2003/350347]
  - 87 **Gao JJ**, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC, Pan KF. Association Between Gut Microbiota and *Helicobacter pylori*-Related Gastric Lesions in a High-Risk Population of Gastric Cancer. *Front Cell Infect Microbiol* 2018; **8**: 202 [PMID: 29971220 DOI: 10.3389/fcimb.2018.00202]
  - 88 **Pereira-Marques J**, Ferreira RM, Pinto-Ribeiro I, Figueiredo C. *Helicobacter pylori* Infection, the Gastric Microbiome and Gastric Cancer. *Adv Exp Med Biol* 2019; **1149**: 195-210 [PMID: 31016631 DOI: 10.1007/5584\_2019\_366]
  - 89 **Guo Y**, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC, Pan KF. Effect of *Helicobacter pylori* on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. *Gut* 2020; **69**: 1598-1607 [PMID: 31857433 DOI: 10.1136/gutjnl-2019-319696]
  - 90 **Rieder G**, Fischer W, Haas R. Interaction of *Helicobacter pylori* with host cells: function of secreted and translocated molecules. *Curr Opin Microbiol* 2005; **8**: 67-73 [PMID: 15694859 DOI: 10.1016/j.mib.2004.12.004]
  - 91 **Li Q**, Liu J, Gong Y, Yuan Y. Serum VacA antibody is associated with risks of peptic ulcer and gastric cancer: A meta-analysis. *Microb Pathog* 2016; **99**: 220-228 [PMID: 27568203 DOI: 10.1016/j.micpath.2016.08.030]
  - 92 **Terebiznik MR**, Raju D, Vázquez CL, Torbrick K, Kulkarni R, Blanke SR, Yoshimori T, Colombo MI, Jones NL. Effect of *Helicobacter pylori*'s vacuolating cytotoxin on the autophagy pathway in gastric epithelial cells. *Autophagy* 2009; **5**: 370-379 [PMID: 19164948 DOI: 10.4161/auto.5.3.7663]
  - 93 **Castañero-Rodríguez N**, Kaakoush NO, Lee WS, Mitchell HM. Dual role of *Helicobacter* and *Campylobacter* species in IBD: a systematic review and meta-analysis. *Gut* 2017; **66**: 235-249 [PMID: 26508508 DOI: 10.1136/gutjnl-2015-310545]
  - 94 **Dubois A**, Borén T. *Helicobacter pylori* is invasive and it may be a facultative intracellular organism. *Cell Microbiol* 2007; **9**: 1108-1116 [PMID: 17388791 DOI: 10.1111/j.1462-5822.2007.00921.x]
  - 95 **Weydig C**, Starzinski-Powitz A, Carra G, Löwer J, Wessler S. CagA-independent disruption of adherence junction complexes involves E-cadherin shedding and implies multiple steps in *Helicobacter pylori* pathogenicity. *Exp Cell Res* 2007; **313**: 3459-3471 [PMID: 17692843 DOI: 10.1016/j.yexcr.2007.07.015]
  - 96 **Saadat I**, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, Lu H, Ohnishi N, Azuma T, Suzuki A, Ohno S, Hatakeyama M. *Helicobacter pylori* CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. *Nature* 2007; **447**: 330-333 [PMID: 17507984 DOI: 10.1038/nature05765]
  - 97 **Murata-Kamiya N**, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM Jr, Azuma T, Hatakeyama M. *Helicobacter pylori* CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. *Oncogene* 2007; **26**: 4617-4626 [PMID: 17237808 DOI: 10.1038/sj.onc.1210251]
  - 98 **Merino JS**, García A, Pastene E, Salas A, Saez K, González CL. *Lactobacillus fermentum* UCO-979C strongly inhibited *Helicobacter pylori* SS1 in *Meriones unguiculatus*. *Benef Microbes* 2018; **9**: 625-627 [PMID: 29633633 DOI: 10.3920/BM2017.0160]
  - 99 **Krzyżek P**. Commentary: Proteomics Analysis Revealed that Crosstalk between *Helicobacter pylori* and *Streptococcus mitis* May Enhance Bacterial Survival and Reduces Carcinogenesis. *Front Microbiol* 2017; **8**: 2381 [PMID: 29238340 DOI: 10.3389/fmicb.2017.02381]
  - 100 **Khosravi Y**, Dieye Y, Loke MF, Goh KL, Vadivelu J. *Streptococcus mitis* induces conversion of *Helicobacter pylori* to coccoid cells during co-culture in vitro. *PLoS One* 2014; **9**: e112214 [PMID: 25386948 DOI: 10.1371/journal.pone.0112214]
  - 101 **Shen Z**, Dzink-Fox J, Wilson KT, Whary MT, Muthupalani S, Piazzuelo MB, Bravo LE, Suerbaum S, Fox JG, Josenhans C. Tu1288 - Co-Colonization of *Helicobacter Pylori* with *Staphylococcus Epidermidis* or *Streptococcus Salivarius* Differ in the Progression of Gastritis in Ins-Gas Mice. *Gastroenterology* 2018; **154**: s924-s925 [DOI: 10.1016/S0016-5085(18)33114-7]
  - 102 **Kazakos EI**, Dorrell N, Polyzos SA, Deretzi G, Kountouras J. Comment on "Effect of biofilm formation by clinical isolates of *Helicobacter pylori* on the efflux-mediated resistance to commonly used antibiotics". *World J Gastroenterol* 2017; **23**: 6194-6196 [PMID: 28970736 DOI: 10.3748/wjg.v23.i33.6194]
  - 103 **Moghadam MT**, Chegini Z, Khoshbayan A, Farahani I, Shariati A. *Helicobacter pylori* Biofilm and New Strategies to Combat it. *Curr Mol Med* 2021; **21**: 549-561 [PMID: 33272177 DOI: 10.2174/1566524020666201203165649]
  - 104 **Pimentel-Nunes P**, Gonçalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque R Jr, Henrique R, Moreira-Dias L, Leite-Moreira AF, Dinis-Ribeiro M. *Helicobacter pylori* induces increased expression of Toll-like receptors and decreased Toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis. *Helicobacter* 2013; **18**: 22-32 [PMID: 23061653 DOI: 10.1111/hel.12008]
  - 105 **González Torre JA**, Cruz-Gómez AJ, Belenguer A, Sanchis-Segura C, Ávila C, Forn C. Hippocampal dysfunction is

associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study. *Mult Scler* 2017; **23**: 1854-1863 [PMID: 28086035 DOI: 10.1177/1352458516688349]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

